Intercept's Ocaliva Eyes Vacant Ground In Europe

Intercept is gearing for launch in Europe following the CHMP's positive opinion for Ocaliva (obeticholic acid) as a treatment for primary biliary cholangitis, an indication for which there is currently only one approved medication in Europe.